Global Targeted Drug ROS1 Inhibitors for NSCLC Market Growth (Status and Outlook) 2025-2031

September 2025 | 70 pages | ID: GF69F06227EEN
LP Information

Abstracts

According to this study, the global Targeted Drug ROS1 Inhibitors for NSCLC market size will reach US$ million by 2031.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

LPI (LP Information)' newest research report, the “Targeted Drug ROS1 Inhibitors for NSCLC Industry Forecast” looks at past sales and reviews total world Targeted Drug ROS1 Inhibitors for NSCLC sales in 2024, providing a comprehensive analysis by region and market sector of projected Targeted Drug ROS1 Inhibitors for NSCLC sales for 2025 through 2031. With Targeted Drug ROS1 Inhibitors for NSCLC sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Targeted Drug ROS1 Inhibitors for NSCLC industry.

This Insight Report provides a comprehensive analysis of the global Targeted Drug ROS1 Inhibitors for NSCLC landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Targeted Drug ROS1 Inhibitors for NSCLC portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Targeted Drug ROS1 Inhibitors for NSCLC market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Targeted Drug ROS1 Inhibitors for NSCLC and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Targeted Drug ROS1 Inhibitors for NSCLC.

This report presents a comprehensive overview, market shares, and growth opportunities of Targeted Drug ROS1 Inhibitors for NSCLC market by product type, application, key players and key regions and countries.

Segmentation by Type:

• Crizotinib
• Lorlatinib
• Entrectinib
• Others

Segmentation by Application:

• Squamous Cell Carcinoma of NSCLC
• Adenocarcinoma of NSCLC
• Large Cell Carcinoma of NSCLC

This report also splits the market by region:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

• Roche
• Pfizer
• Beacon Pharma Limited
• Drug International Limted
• Incepta Pharmaceuticals

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Targeted Drug ROS1 Inhibitors for NSCLC Market Size (2020-2031)
  2.1.2 Targeted Drug ROS1 Inhibitors for NSCLC Market Size CAGR by Region (2020 VS 2024 VS 2031)
  2.1.3 World Current & Future Analysis for Targeted Drug ROS1 Inhibitors for NSCLC by Country/Region (2020, 2024 & 2031)
2.2 Targeted Drug ROS1 Inhibitors for NSCLC Segment by Type
  2.2.1 Crizotinib
  2.2.2 Lorlatinib
  2.2.3 Entrectinib
  2.2.4 Others
2.3 Targeted Drug ROS1 Inhibitors for NSCLC Market Size by Type
  2.3.1 Targeted Drug ROS1 Inhibitors for NSCLC Market Size CAGR by Type (2020 VS 2024 VS 2031)
  2.3.2 Global Targeted Drug ROS1 Inhibitors for NSCLC Market Size Market Share by Type (2020-2025)
2.4 Targeted Drug ROS1 Inhibitors for NSCLC Segment by Application
  2.4.1 Squamous Cell Carcinoma of NSCLC
  2.4.2 Adenocarcinoma of NSCLC
  2.4.3 Large Cell Carcinoma of NSCLC
2.5 Targeted Drug ROS1 Inhibitors for NSCLC Market Size by Application
  2.5.1 Targeted Drug ROS1 Inhibitors for NSCLC Market Size CAGR by Application (2020 VS 2024 VS 2031)
  2.5.2 Global Targeted Drug ROS1 Inhibitors for NSCLC Market Size Market Share by Application (2020-2025)

3 TARGETED DRUG ROS1 INHIBITORS FOR NSCLC MARKET SIZE BY PLAYER

3.1 Targeted Drug ROS1 Inhibitors for NSCLC Market Size Market Share by Player
  3.1.1 Global Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Player (2020-2025)
  3.1.2 Global Targeted Drug ROS1 Inhibitors for NSCLC Revenue Market Share by Player (2020-2025)
3.2 Global Targeted Drug ROS1 Inhibitors for NSCLC Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
  3.3.1 Competition Landscape Analysis
  3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion

4 TARGETED DRUG ROS1 INHIBITORS FOR NSCLC BY REGION

4.1 Targeted Drug ROS1 Inhibitors for NSCLC Market Size by Region (2020-2025)
4.2 Global Targeted Drug ROS1 Inhibitors for NSCLC Annual Revenue by Country/Region (2020-2025)
4.3 Americas Targeted Drug ROS1 Inhibitors for NSCLC Market Size Growth (2020-2025)
4.4 APAC Targeted Drug ROS1 Inhibitors for NSCLC Market Size Growth (2020-2025)
4.5 Europe Targeted Drug ROS1 Inhibitors for NSCLC Market Size Growth (2020-2025)
4.6 Middle East & Africa Targeted Drug ROS1 Inhibitors for NSCLC Market Size Growth (2020-2025)

5 AMERICAS

5.1 Americas Targeted Drug ROS1 Inhibitors for NSCLC Market Size by Country (2020-2025)
5.2 Americas Targeted Drug ROS1 Inhibitors for NSCLC Market Size by Type (2020-2025)
5.3 Americas Targeted Drug ROS1 Inhibitors for NSCLC Market Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC Targeted Drug ROS1 Inhibitors for NSCLC Market Size by Region (2020-2025)
6.2 APAC Targeted Drug ROS1 Inhibitors for NSCLC Market Size by Type (2020-2025)
6.3 APAC Targeted Drug ROS1 Inhibitors for NSCLC Market Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia

7 EUROPE

7.1 Europe Targeted Drug ROS1 Inhibitors for NSCLC Market Size by Country (2020-2025)
7.2 Europe Targeted Drug ROS1 Inhibitors for NSCLC Market Size by Type (2020-2025)
7.3 Europe Targeted Drug ROS1 Inhibitors for NSCLC Market Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Targeted Drug ROS1 Inhibitors for NSCLC by Region (2020-2025)
8.2 Middle East & Africa Targeted Drug ROS1 Inhibitors for NSCLC Market Size by Type (2020-2025)
8.3 Middle East & Africa Targeted Drug ROS1 Inhibitors for NSCLC Market Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 GLOBAL TARGETED DRUG ROS1 INHIBITORS FOR NSCLC MARKET FORECAST

10.1 Global Targeted Drug ROS1 Inhibitors for NSCLC Forecast by Region (2026-2031)
  10.1.1 Global Targeted Drug ROS1 Inhibitors for NSCLC Forecast by Region (2026-2031)
  10.1.2 Americas Targeted Drug ROS1 Inhibitors for NSCLC Forecast
  10.1.3 APAC Targeted Drug ROS1 Inhibitors for NSCLC Forecast
  10.1.4 Europe Targeted Drug ROS1 Inhibitors for NSCLC Forecast
  10.1.5 Middle East & Africa Targeted Drug ROS1 Inhibitors for NSCLC Forecast
10.2 Americas Targeted Drug ROS1 Inhibitors for NSCLC Forecast by Country (2026-2031)
  10.2.1 United States Market Targeted Drug ROS1 Inhibitors for NSCLC Forecast
  10.2.2 Canada Market Targeted Drug ROS1 Inhibitors for NSCLC Forecast
  10.2.3 Mexico Market Targeted Drug ROS1 Inhibitors for NSCLC Forecast
  10.2.4 Brazil Market Targeted Drug ROS1 Inhibitors for NSCLC Forecast
10.3 APAC Targeted Drug ROS1 Inhibitors for NSCLC Forecast by Region (2026-2031)
  10.3.1 China Targeted Drug ROS1 Inhibitors for NSCLC Market Forecast
  10.3.2 Japan Market Targeted Drug ROS1 Inhibitors for NSCLC Forecast
  10.3.3 Korea Market Targeted Drug ROS1 Inhibitors for NSCLC Forecast
  10.3.4 Southeast Asia Market Targeted Drug ROS1 Inhibitors for NSCLC Forecast
  10.3.5 India Market Targeted Drug ROS1 Inhibitors for NSCLC Forecast
  10.3.6 Australia Market Targeted Drug ROS1 Inhibitors for NSCLC Forecast
10.4 Europe Targeted Drug ROS1 Inhibitors for NSCLC Forecast by Country (2026-2031)
  10.4.1 Germany Market Targeted Drug ROS1 Inhibitors for NSCLC Forecast
  10.4.2 France Market Targeted Drug ROS1 Inhibitors for NSCLC Forecast
  10.4.3 UK Market Targeted Drug ROS1 Inhibitors for NSCLC Forecast
  10.4.4 Italy Market Targeted Drug ROS1 Inhibitors for NSCLC Forecast
  10.4.5 Russia Market Targeted Drug ROS1 Inhibitors for NSCLC Forecast
10.5 Middle East & Africa Targeted Drug ROS1 Inhibitors for NSCLC Forecast by Region (2026-2031)
  10.5.1 Egypt Market Targeted Drug ROS1 Inhibitors for NSCLC Forecast
  10.5.2 South Africa Market Targeted Drug ROS1 Inhibitors for NSCLC Forecast
  10.5.3 Israel Market Targeted Drug ROS1 Inhibitors for NSCLC Forecast
  10.5.4 Turkey Market Targeted Drug ROS1 Inhibitors for NSCLC Forecast
10.6 Global Targeted Drug ROS1 Inhibitors for NSCLC Forecast by Type (2026-2031)
10.7 Global Targeted Drug ROS1 Inhibitors for NSCLC Forecast by Application (2026-2031)
  10.7.1 GCC Countries Market Targeted Drug ROS1 Inhibitors for NSCLC Forecast

11 KEY PLAYERS ANALYSIS

11.1 Roche
  11.1.1 Roche Company Information
  11.1.2 Roche Targeted Drug ROS1 Inhibitors for NSCLC Product Offered
  11.1.3 Roche Targeted Drug ROS1 Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
  11.1.4 Roche Main Business Overview
  11.1.5 Roche Latest Developments
11.2 Pfizer
  11.2.1 Pfizer Company Information
  11.2.2 Pfizer Targeted Drug ROS1 Inhibitors for NSCLC Product Offered
  11.2.3 Pfizer Targeted Drug ROS1 Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
  11.2.4 Pfizer Main Business Overview
  11.2.5 Pfizer Latest Developments
11.3 Beacon Pharma Limited
  11.3.1 Beacon Pharma Limited Company Information
  11.3.2 Beacon Pharma Limited Targeted Drug ROS1 Inhibitors for NSCLC Product Offered
  11.3.3 Beacon Pharma Limited Targeted Drug ROS1 Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
  11.3.4 Beacon Pharma Limited Main Business Overview
  11.3.5 Beacon Pharma Limited Latest Developments
11.4 Drug International Limted
  11.4.1 Drug International Limted Company Information
  11.4.2 Drug International Limted Targeted Drug ROS1 Inhibitors for NSCLC Product Offered
  11.4.3 Drug International Limted Targeted Drug ROS1 Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
  11.4.4 Drug International Limted Main Business Overview
  11.4.5 Drug International Limted Latest Developments
11.5 Incepta Pharmaceuticals
  11.5.1 Incepta Pharmaceuticals Company Information
  11.5.2 Incepta Pharmaceuticals Targeted Drug ROS1 Inhibitors for NSCLC Product Offered
  11.5.3 Incepta Pharmaceuticals Targeted Drug ROS1 Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
  11.5.4 Incepta Pharmaceuticals Main Business Overview
  11.5.5 Incepta Pharmaceuticals Latest Developments

12 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Targeted Drug ROS1 Inhibitors for NSCLC Market Size CAGR by Region (2020 VS 2024 VS 2031) & ($ millions)
Table 2. Targeted Drug ROS1 Inhibitors for NSCLC Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Crizotinib
Table 4. Major Players of Lorlatinib
Table 5. Major Players of Entrectinib
Table 6. Major Players of Others
Table 7. Targeted Drug ROS1 Inhibitors for NSCLC Market Size CAGR by Type (2020 VS 2024 VS 2031) & ($ millions)
Table 8. Global Targeted Drug ROS1 Inhibitors for NSCLC Market Size by Type (2020-2025) & ($ millions)
Table 9. Global Targeted Drug ROS1 Inhibitors for NSCLC Market Size Market Share by Type (2020-2025)
Table 10. Targeted Drug ROS1 Inhibitors for NSCLC Market Size CAGR by Application (2020 VS 2024 VS 2031) & ($ millions)
Table 11. Global Targeted Drug ROS1 Inhibitors for NSCLC Market Size by Application (2020-2025) & ($ millions)
Table 12. Global Targeted Drug ROS1 Inhibitors for NSCLC Market Size Market Share by Application (2020-2025)
Table 13. Global Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Player (2020-2025) & ($ millions)
Table 14. Global Targeted Drug ROS1 Inhibitors for NSCLC Revenue Market Share by Player (2020-2025)
Table 15. Targeted Drug ROS1 Inhibitors for NSCLC Key Players Head office and Products Offered
Table 16. Targeted Drug ROS1 Inhibitors for NSCLC Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 17. New Products and Potential Entrants
Table 18. Mergers & Acquisitions, Expansion
Table 19. Global Targeted Drug ROS1 Inhibitors for NSCLC Market Size by Region (2020-2025) & ($ millions)
Table 20. Global Targeted Drug ROS1 Inhibitors for NSCLC Market Size Market Share by Region (2020-2025)
Table 21. Global Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Country/Region (2020-2025) & ($ millions)
Table 22. Global Targeted Drug ROS1 Inhibitors for NSCLC Revenue Market Share by Country/Region (2020-2025)
Table 23. Americas Targeted Drug ROS1 Inhibitors for NSCLC Market Size by Country (2020-2025) & ($ millions)
Table 24. Americas Targeted Drug ROS1 Inhibitors for NSCLC Market Size Market Share by Country (2020-2025)
Table 25. Americas Targeted Drug ROS1 Inhibitors for NSCLC Market Size by Type (2020-2025) & ($ millions)
Table 26. Americas Targeted Drug ROS1 Inhibitors for NSCLC Market Size Market Share by Type (2020-2025)
Table 27. Americas Targeted Drug ROS1 Inhibitors for NSCLC Market Size by Application (2020-2025) & ($ millions)
Table 28. Americas Targeted Drug ROS1 Inhibitors for NSCLC Market Size Market Share by Application (2020-2025)
Table 29. APAC Targeted Drug ROS1 Inhibitors for NSCLC Market Size by Region (2020-2025) & ($ millions)
Table 30. APAC Targeted Drug ROS1 Inhibitors for NSCLC Market Size Market Share by Region (2020-2025)
Table 31. APAC Targeted Drug ROS1 Inhibitors for NSCLC Market Size by Type (2020-2025) & ($ millions)
Table 32. APAC Targeted Drug ROS1 Inhibitors for NSCLC Market Size by Application (2020-2025) & ($ millions)
Table 33. Europe Targeted Drug ROS1 Inhibitors for NSCLC Market Size by Country (2020-2025) & ($ millions)
Table 34. Europe Targeted Drug ROS1 Inhibitors for NSCLC Market Size Market Share by Country (2020-2025)
Table 35. Europe Targeted Drug ROS1 Inhibitors for NSCLC Market Size by Type (2020-2025) & ($ millions)
Table 36. Europe Targeted Drug ROS1 Inhibitors for NSCLC Market Size by Application (2020-2025) & ($ millions)
Table 37. Middle East & Africa Targeted Drug ROS1 Inhibitors for NSCLC Market Size by Region (2020-2025) & ($ millions)
Table 38. Middle East & Africa Targeted Drug ROS1 Inhibitors for NSCLC Market Size by Type (2020-2025) & ($ millions)
Table 39. Middle East & Africa Targeted Drug ROS1 Inhibitors for NSCLC Market Size by Application (2020-2025) & ($ millions)
Table 40. Key Market Drivers & Growth Opportunities of Targeted Drug ROS1 Inhibitors for NSCLC
Table 41. Key Market Challenges & Risks of Targeted Drug ROS1 Inhibitors for NSCLC
Table 42. Key Industry Trends of Targeted Drug ROS1 Inhibitors for NSCLC
Table 43. Global Targeted Drug ROS1 Inhibitors for NSCLC Market Size Forecast by Region (2026-2031) & ($ millions)
Table 44. Global Targeted Drug ROS1 Inhibitors for NSCLC Market Size Market Share Forecast by Region (2026-2031)
Table 45. Global Targeted Drug ROS1 Inhibitors for NSCLC Market Size Forecast by Type (2026-2031) & ($ millions)
Table 46. Global Targeted Drug ROS1 Inhibitors for NSCLC Market Size Forecast by Application (2026-2031) & ($ millions)
Table 47. Roche Details, Company Type, Targeted Drug ROS1 Inhibitors for NSCLC Area Served and Its Competitors
Table 48. Roche Targeted Drug ROS1 Inhibitors for NSCLC Product Offered
Table 49. Roche Targeted Drug ROS1 Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 50. Roche Main Business
Table 51. Roche Latest Developments
Table 52. Pfizer Details, Company Type, Targeted Drug ROS1 Inhibitors for NSCLC Area Served and Its Competitors
Table 53. Pfizer Targeted Drug ROS1 Inhibitors for NSCLC Product Offered
Table 54. Pfizer Targeted Drug ROS1 Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 55. Pfizer Main Business
Table 56. Pfizer Latest Developments
Table 57. Beacon Pharma Limited Details, Company Type, Targeted Drug ROS1 Inhibitors for NSCLC Area Served and Its Competitors
Table 58. Beacon Pharma Limited Targeted Drug ROS1 Inhibitors for NSCLC Product Offered
Table 59. Beacon Pharma Limited Targeted Drug ROS1 Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 60. Beacon Pharma Limited Main Business
Table 61. Beacon Pharma Limited Latest Developments
Table 62. Drug International Limted Details, Company Type, Targeted Drug ROS1 Inhibitors for NSCLC Area Served and Its Competitors
Table 63. Drug International Limted Targeted Drug ROS1 Inhibitors for NSCLC Product Offered
Table 64. Drug International Limted Targeted Drug ROS1 Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 65. Drug International Limted Main Business
Table 66. Drug International Limted Latest Developments
Table 67. Incepta Pharmaceuticals Details, Company Type, Targeted Drug ROS1 Inhibitors for NSCLC Area Served and Its Competitors
Table 68. Incepta Pharmaceuticals Targeted Drug ROS1 Inhibitors for NSCLC Product Offered
Table 69. Incepta Pharmaceuticals Targeted Drug ROS1 Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 70. Incepta Pharmaceuticals Main Business
Table 71. Incepta Pharmaceuticals Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Targeted Drug ROS1 Inhibitors for NSCLC Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Targeted Drug ROS1 Inhibitors for NSCLC Market Size Growth Rate (2020-2031) ($ millions)
Figure 6. Targeted Drug ROS1 Inhibitors for NSCLC Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 7. Targeted Drug ROS1 Inhibitors for NSCLC Sales Market Share by Country/Region (2024)
Figure 8. Targeted Drug ROS1 Inhibitors for NSCLC Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 9. Global Targeted Drug ROS1 Inhibitors for NSCLC Market Size Market Share by Type in 2024
Figure 10. Targeted Drug ROS1 Inhibitors for NSCLC in Squamous Cell Carcinoma of NSCLC
Figure 11. Global Targeted Drug ROS1 Inhibitors for NSCLC Market: Squamous Cell Carcinoma of NSCLC (2020-2025) & ($ millions)
Figure 12. Targeted Drug ROS1 Inhibitors for NSCLC in Adenocarcinoma of NSCLC
Figure 13. Global Targeted Drug ROS1 Inhibitors for NSCLC Market: Adenocarcinoma of NSCLC (2020-2025) & ($ millions)
Figure 14. Targeted Drug ROS1 Inhibitors for NSCLC in Large Cell Carcinoma of NSCLC
Figure 15. Global Targeted Drug ROS1 Inhibitors for NSCLC Market: Large Cell Carcinoma of NSCLC (2020-2025) & ($ millions)
Figure 16. Global Targeted Drug ROS1 Inhibitors for NSCLC Market Size Market Share by Application in 2024
Figure 17. Global Targeted Drug ROS1 Inhibitors for NSCLC Revenue Market Share by Player in 2024
Figure 18. Global Targeted Drug ROS1 Inhibitors for NSCLC Market Size Market Share by Region (2020-2025)
Figure 19. Americas Targeted Drug ROS1 Inhibitors for NSCLC Market Size 2020-2025 ($ millions)
Figure 20. APAC Targeted Drug ROS1 Inhibitors for NSCLC Market Size 2020-2025 ($ millions)
Figure 21. Europe Targeted Drug ROS1 Inhibitors for NSCLC Market Size 2020-2025 ($ millions)
Figure 22. Middle East & Africa Targeted Drug ROS1 Inhibitors for NSCLC Market Size 2020-2025 ($ millions)
Figure 23. Americas Targeted Drug ROS1 Inhibitors for NSCLC Value Market Share by Country in 2024
Figure 24. United States Targeted Drug ROS1 Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 25. Canada Targeted Drug ROS1 Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 26. Mexico Targeted Drug ROS1 Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 27. Brazil Targeted Drug ROS1 Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 28. APAC Targeted Drug ROS1 Inhibitors for NSCLC Market Size Market Share by Region in 2024
Figure 29. APAC Targeted Drug ROS1 Inhibitors for NSCLC Market Size Market Share by Type (2020-2025)
Figure 30. APAC Targeted Drug ROS1 Inhibitors for NSCLC Market Size Market Share by Application (2020-2025)
Figure 31. China Targeted Drug ROS1 Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 32. Japan Targeted Drug ROS1 Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 33. South Korea Targeted Drug ROS1 Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 34. Southeast Asia Targeted Drug ROS1 Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 35. India Targeted Drug ROS1 Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 36. Australia Targeted Drug ROS1 Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 37. Europe Targeted Drug ROS1 Inhibitors for NSCLC Market Size Market Share by Country in 2024
Figure 38. Europe Targeted Drug ROS1 Inhibitors for NSCLC Market Size Market Share by Type (2020-2025)
Figure 39. Europe Targeted Drug ROS1 Inhibitors for NSCLC Market Size Market Share by Application (2020-2025)
Figure 40. Germany Targeted Drug ROS1 Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 41. France Targeted Drug ROS1 Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 42. UK Targeted Drug ROS1 Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 43. Italy Targeted Drug ROS1 Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 44. Russia Targeted Drug ROS1 Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 45. Middle East & Africa Targeted Drug ROS1 Inhibitors for NSCLC Market Size Market Share by Region (2020-2025)
Figure 46. Middle East & Africa Targeted Drug ROS1 Inhibitors for NSCLC Market Size Market Share by Type (2020-2025)
Figure 47. Middle East & Africa Targeted Drug ROS1 Inhibitors for NSCLC Market Size Market Share by Application (2020-2025)
Figure 48. Egypt Targeted Drug ROS1 Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 49. South Africa Targeted Drug ROS1 Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 50. Israel Targeted Drug ROS1 Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 51. Turkey Targeted Drug ROS1 Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 52. GCC Countries Targeted Drug ROS1 Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 53. Americas Targeted Drug ROS1 Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 54. APAC Targeted Drug ROS1 Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 55. Europe Targeted Drug ROS1 Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 56. Middle East & Africa Targeted Drug ROS1 Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 57. United States Targeted Drug ROS1 Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 58. Canada Targeted Drug ROS1 Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 59. Mexico Targeted Drug ROS1 Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 60. Brazil Targeted Drug ROS1 Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 61. China Targeted Drug ROS1 Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 62. Japan Targeted Drug ROS1 Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 63. Korea Targeted Drug ROS1 Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 64. Southeast Asia Targeted Drug ROS1 Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 65. India Targeted Drug ROS1 Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 66. Australia Targeted Drug ROS1 Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 67. Germany Targeted Drug ROS1 Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 68. France Targeted Drug ROS1 Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 69. UK Targeted Drug ROS1 Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 70. Italy Targeted Drug ROS1 Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 71. Russia Targeted Drug ROS1 Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 72. Egypt Targeted Drug ROS1 Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 73. South Africa Targeted Drug ROS1 Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 74. Israel Targeted Drug ROS1 Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 75. Turkey Targeted Drug ROS1 Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 76. Global Targeted Drug ROS1 Inhibitors for NSCLC Market Size Market Share Forecast by Type (2026-2031)
Figure 77. Global Targeted Drug ROS1 Inhibitors for NSCLC Market Size Market Share Forecast by Application (2026-2031)
Figure 78. GCC Countries Targeted Drug ROS1 Inhibitors for NSCLC Market Size 2026-2031 ($ millions)